A retrospective comparison of inappropriate prescribing of psychotropics in three Norwegian nursing homes in 2000 and 2016 with prescribing quality indicators by Schjøtt, Jan & Assmus, Jörg
RESEARCH ARTICLE Open Access
A retrospective comparison of
inappropriate prescribing of psychotropics
in three Norwegian nursing homes in 2000
and 2016 with prescribing quality
indicators
Jan Schjøtt1,2* and Jörg Aßmus3
Abstract
Background: Inappropriate prescribing of psychotropics is a persistent and prevalent problem in nursing homes.
The present study compared inappropriate prescribing of psychotropics in nursing homes 16 years apart with
prescribing quality indicators. The purpose was to identify any change in inappropriate prescribing of relevance
for medical informatics.
Methods: Three Norwegian nursing homes were audited in 2000 and 2016 with regard to prescribing quality.
Psychotropics among 386 patients in 2000, and 416 patients in 2016, included combinations of antidepressants,
antipsychotics, anxiolytics-hypnotics, and antiepileptics. Prescribing quality indicators included psychotropic
polypharmacy (defined as concurrent use of three or more psychotropics) and potential inappropriate psychotropic
substances or combinations. Furthermore, potential clinically relevant psychotropic interactions were classified as
pharmacodynamic or pharmacokinetic using an interaction database. The first ranked (most important) interaction in
each patient was selected with the following importance of categories in the database; recommended action
> documentation > severity. Three levels (from low to high) within each category were used for ranking.
Results: From 2000 to 2016, psychotropic polypharmacy increased from 6.2 to 29.6%, potential inappropriate
psychotropic substances was reduced from 17.9 to 11.3% and potential inappropriate psychotropic combinations
increased from 7.8 to 27.9%. Changes in polypharmacy and combinations were predominantly associated with
prescribing of anxiolytics-hypnotics. Sixty-three patients (16.3%) had psychotropic interactions in 2000 increasing to 146
patients (35.1%) in 2016. The increase in interactions was associated with prescribing of antidepressants. First ranked
interactions, more than 60% of all interactions in both years, were increasingly pharmacodynamic, from 69.9 to 91.0%.
Interactions in 2016 were associated with a lower level of recommended action and documentation, but not
severity compared to 2000. The inappropriate prescribing of antipsychotics and antiepileptics was reduced in
2016 compared to 2000.
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Conclusions: Using prescribing quality indicators we observed the importance of antidepressants and
anxiolytics-hypnotics for inappropriate prescribing in 2016 while the role of antipsychotics and antiepileptics
were reduced compared to 2000. A change to mainly pharmacodynamic interactions that lack good
documentation was also observed. The present findings can be used for medical informatics-based
approaches to address specific problems with prescribing, and prescribing quality indicators, in Norwegian
nursing homes.
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Background
Use of one or more psychotropic drugs (e.g. psychotro-
pics like antidepressants, antipsychotics, anxiolytics and
hypnotics among others) is common in nursing homes
[1–3]. Use of psychotropics is high among patients with
dementia (about 80% of nursing home patients), and
psychotropics are used in treatment of agitation, delu-
sions, anxiety, depression, and sleep problems [4, 5]. In-
appropriate treatment with multiple psychotropics has
been identified as the most frequent drug-related prob-
lem in nursing homes [6, 7]. A recent cross-sectional
analysis among 451 nursing homes in France found that
polypharmacy and prescribing of potentially inappropri-
ate medications mainly concerned psychotropics [8].
Psychotropics are associated with several adverse effects
in older adults, most importantly risk of fall injuries,
hospitalisations and mortality [9, 10].
Prescribing quality indicators are recommended to
support clinical decision making in pharmacotherapy
[11]. Indicators for inappropriate use of psychotropics
include “concurrent use of three or more psychotropics”
[12]. This indicator is considered to be a proxy for poly-
pharmacy with risk of adverse effects and psychotropic
interactions (PIs). Potentially inappropriate psychotropic
combinations (PICP) or potentially inappropriate psy-
chotropic substances (PIPS) are more specific indicators
compared to “concurrent use of three or more psycho-
tropics”, particularly with respect to increased risk of ad-
verse events among the elderly [12]. Drug interaction
databases are also frequently used to assess prescribing
quality in nursing homes [7, 8]. Considering the quality
of medical informatics and decision support, subscrip-
tion databases should be preferred to open access data-
bases or prescribing and dispensing software systems
[11, 13, 14].
The present study compared prescribing of psychotro-
pics in 2000 and 2016 with prescribing quality indicators.
The purpose was to identify any change in inappropriate
prescribing of psychotropics with regard to polypharmacy,
PICP, PIPS, and PIs. Inappropriate prescribing of psycho-
tropics is a persistent and prevalent problem in nursing
homes in Europe despite the introduction of several
prescribing quality indicators [6–8, 15]. Identification of
current and historical problems with inappropriate pre-
scribing, and prescribing quality indicators, could be useful




One-day, point-prevalence of psychotropic prescribing
in a convenience (non-randomised) sample was collected
from the same three nursing homes in Bergen, Norway
16 years apart. No clinical or personal information other
than patients’age and gender was collected. Nor was in-
formation pertaining to physicians, other staff, or details
concerning organisation of the nursing homes. Only
patients’aged ≥ 65 years were included at both sampling
times. Researchers were blinded to patients’nursing
home residence in 2016.
The three nursing homes in 2016 included regular
units that provided long-term care, respite care, and re-
habilitation as well as units for short-term care. They
also included special care units that provide sheltered
care for patients with dementia and psychogeriatric dis-
eases. Thus, they reflect the transition in nursing homes
from 2000 to 2016 with institutions consisting of mainly
regular units to institutions that also provide various
more specialized units. The two audits of prescribing
were regarded as representative for identifying inappro-
priate prescribing of psychotropics.
Psychotropics
The information on prescribing of psychotropics was
manually collected from medical charts (cardex) by
pharmacists in March 2000. Data included prescribed
psychotropics, time of administration and respective
doses. In March 2016, similar data were retrieved
automatically from electronic charts. Psychotropics
were classified according to the Anatomical Thera-
peutic Chemical (ATC) classification system [16], and
included antipsychotics (ATC-code N05A), anxiolytics
(N05B), hypnotics (N05C), antidepressants (N06A)
and antiepileptics (N03A). Anxiolytics and hypnotics
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were collapsed into one category (anxiolytics-hypno-
tics) based on the assumption that the two categories
have comparable adverse effects among nursing home
patients. Antiepileptics are increasingly prescribed for
psychiatric indications in Norway, and epilepsy increases
with age [17]. Of relevance for inappropriate prescribing
of psychotropics, data concerning all prescribed psycho-
tropics (regularly prescribed and additional drugs as
needed) were included [18]. Concurrent use of psychotro-
pics from a similar ATC category is not uncommon in
nursing homes, but resulted in a single registration for
each patient (e.g. the patient uses ≥ 1 antidepressants).
Polypharmacy, PICP and PIPS
Polypharmacy was defined as concurrent use of three or
more psychotropics [12]. PICP were defined as combina-
tions of two or more psychotropics from the same
ATC-category. PIPS were defined as long-acting benzo-
diazepines and psychotropics with anticholinergic effects
[12]. PICP were defined from the third level (pharmaco-
logical subgroup; e.g N05A, antipsychotics), and polyphar-
macy and PIPS were defined at the fifth level (chemical
substance; e.g. N05A, risperidone) in the ATC-classification
system [16]. The prescribing quality indicators above are
recommended for patients aged 75 years or older, but could
be relevant for younger patients (65 years or older) in nurs-
ing homes, and were used accordingly in the present study.
PIs
We also assessed the most important PIs in the prescrip-
tion data of the respective years. The first ranked PI in a
patient was selected by use of the subscription inter-
action database Stockley’s Interaction Alerts (SIA) [19].
SIA provides consistent albeit briefer information on
drug interactions compared to Stockley’s Drug Interac-
tions, and describes classification of the clinical rele-
vance of a drug interaction. A clinically relevant PI in
SIA is classified with the following three categories: rec-
ommended action, severity, and documentation. In SIA,
the recommended action for a clinically relevant PI is ei-
ther “informative”, “monitor”, “adjust dose”, or “avoid”.
Recommended action for a clinically relevant PI in the
present study was defined by collapsing “monitor” and
“adjust dose” into the following three levels (from low to
high); “informative”, “monitor or adjust dose”, or “avoid”.
In the present study, severity was classified (from low to
high) as “mild”, “moderate” or “high” in concordance
with SIA. Documentation in SIA is classified with four
levels; “theoretical”, “case”, “study” or “extensive”. “Ex-
tensive” is an option for documentation of interactions
where the information provided is based on numerous
small or medium size studies or several large studies usu-
ally supported by case reports [19]. Documentation of a
clinically relevant PI in the present study was defined by
collapsing “study” and “extensive” to aquire the following
levels (from low to high); “theoretical”, “case”, or “study”.
The first ranked PI in each patient was defined by the fol-
lowing hierarchy of categories and levels; recommended
action (avoid > monitor or adjust dose > informative) >
documentation (study > case > theoretical) > severity (se-
vere > moderate > mild). The order of the categories were
based on our experience that many PIs may be described
as potentially severe, but recommended action (e.g. con-
traindicated) and documentation (study) is of importance
when providing drug information. The number of concur-
rent PIs was registered for each patient. A clinical pharma-
cologist (JS) defined each PI as pharmacodynamic or
pharmacokinetic based on the description in SIA. If a
pharmacokinetic PI contained an additional description of
a pharmacodynamic effect which could not be explained
by a change in plasma level of one or both drugs, the PI
was defined as pharmacokinetic.
Outcomes and predictors
The study investigated the appearance of different types
of psychotropics as well as their combinations and inter-
actions as outcomes. Predictors of having ≥ 1 PIs among
patients with ≥ 2 concurrent psychotropics included age,
gender, number of psychotropics, and use of antidepres-
sants, antipsychotics, anxiolytics-hypnotics or antiepilep-
tics. Dichotomous variables were coded as 0 or 1 for
absence or presence of a quality (e.g. no use of antide-
pressants = 0; use of ≥ 1 antidepressants = 1). Age and
number of psychotropics were introduced in the model
as continuous variables.
Statistical analysis
Comparison of continuous variables including age and
number of psychotropics or PIs was performed by the
Mann-Whitney U-test. Comparisons of proportions was
performed by Chi-square test or Fischer’s Exact test. The
association between the predictors and the appearance
of PIs was assessed using a logistic regression model in
three steps. In the first step we estimated the univariate
model for each predictor and in the second we estimated
the fully adjusted model containing all predictors. In the
third step we defined the final model including only pre-
dictors with a p-value < 0.25 in one of the first steps.
Predictors were examined for multicollinearity by linear
regression analysis. P-values < 0.01 were accepted as sta-
tistically significant. SPSS version 24 (IBM Corp, Armonk,
NY) was used for data analysis.
Results
Study population
In 2000 there were 386 patients in the three nursing
homes increasing to 416 in 2016. The proportion of male
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residents increased from 26.4% to 33.9% in 2016. Mean
age ± standard deviation (SD) among patients was 84.6
± 7.2 years in 2000, and 84.3 ± 8.1 years in 2016 (p =
0.704). Women were older than men at both sampling
times, but there were no significant age differences be-
tween the time-points within each gender. There were
no significant differences with regard to age or gender
among subgroups of patients who used psychotropics
or had PIs. No patients were younger than 65 years in
2000. Twenty patients aged 23 to 64 years were ex-
cluded from the material in 2016.
Psychotropics
Twenty-two different psychotropics were prescribed in
both 2000 and 2016, while 14 and 13 psychotropics were
unique for 2000 and 2016, respectively (Table 1). Rela-
tively few patients (< 5%) were prescribed unique drugs in
2000. Three of the unique drugs in 2016 were prescribed
to > 10% of the patients. The five most frequent psycho-
tropics prescribed to patients in 2000 were citalopram,
oxazepam, zopiclone, risperidone and carbamazepine. In
2016, the most frequent prescribed were oxazepam, zopi-
clone, mirtazapine, quetiapine and escitalopram. Among
psychotropics prescribed in both 2000 and 2016, the in-
crease of oxazepam and zopiclone was most striking. In
2000, 386 patients were prescribed 352 psychotropics
compared to 416 patients and 765 psychotropics in 2016.
On average, 0.91 psychotropics per person in 2000 in-
creased to 1.84 in 2016 in the three nursing homes. The
median number of concurrent psychotropics was two in
both years. A range of two to four concurrent psychotro-
pics in 2000 increased to two to six in 2016.
Polypharmacy, PICP and PIPS
Comparison of prescribing psychotropics, including psy-
chotropic polypharmacy, in the three nursing homes is
shown in Table 2. Psychotropic polypharmacy increased
significantly from 6.2% to 29.6% (p < 0.001). The use of
antidepressants and anxiolytic-hypnotics increased in
Table 1 Psychotropics prescribed only in 2000, in both years, and only in 2016 in three nursing homes with 386 and 416 patients
the respective years
2000 2000 and 2016 2016
Drug Patients n (%) Drug Patients n (%) Patients n (%) Drug Patients n (%)
Patients 386 (100.0) 386 (100.0) 416 (100.0) 416 (100.0)
Antidepressants Clomipramine 1 (0.3) Amitriptyline 8 (2.1) 2 (0.5) Bupropione 4 (1.0)
Doxepine 2 (0.5) Citalopram 51 (13.2) 25 (6.0) Escitalopram 57 (13.7)
Nortriptyline 6 (1.6) Mianserin 15 (3.9) 10 (2.4) Mirtazapine 89 (21.4)
Paroxetine 16 (4.1) Sertralin 8 (2.1) 15 (3.6) Moclobemide 1 (0.2)
Venlafaxine 11 (2.6)
Antipsychotics Chlorpromazine 7 (1.8) Chlorprotixene 2 (0.5) 3 (0.7) Clozapine 4 (1.0)
Flupenthixol 3 (0.8) Haloperidol 14 (3.6) 27 (6.5) Quetiapine 72 (17.3)
Fluphenazine 1 (0.3) Levomepromazine 18 (4.7) 4 (1.0)
Melperon 5 (1.3) Lithium 2 (0.5) 1 (0.2)
Perphenazine 3 (0.8) Olanzapin 7 (1.8) 13 (3.1)
Sertindole 1 (0.3) Risperidon 33 (8.5) 8 (1.9)
Prochlorperazine 2 (0.5) 1 (0.2)
Zuclopentixol 4 (1.0) 2 (0.5)
Anxiolytics-hypnotics Buspirone 1 (0.3) Diazepam 14 (3.6) 33 (7.9) Clomethiazole 20 (4.8)
Flunitrazepam 5 (1.3) Oxazepam 40 (10.4) 164 (39.4) Melatonin 6 (1.4)
Hydroxyzine 3 (0.8) 3 (0.7) Midazolam 19 (4.6)
Nitrazepam 11 (2.8) 2 (0.5)
Zolpidem 2 (0.5) 5 (1.2)
Zopiclone 34 (8.8) 113 (27.2)
Antiepileptics Phenobarbital 3 (0.8) Gabapentin 1 (0.3) 8 (1.9) Lamotrigine 4 (1.0)
Phenytoin 4 (1.0) Carbamazepine 23 (5.6) 6 (1.4) Levetiracetam 17 (4.1)
Clonazepam 2 (0.5) 1 (0.2) Pregabalin 5 (1.2)
Valproic acid 2 (0.5) 9 (2.2)
Notice that patients can be prescribed several psychotropics
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general, but also among patients with PIs. Table 3 shows
use of combinations of psychotropics, PICP and PIPS. Pre-
scribing of combinations of antidepressants and anxiolytic-
hypnotics increased between the two years. In 2016,
fourteen patients (3.4%) were prescribed combinations of
two antidepressants and two anxiolytics-hypnotics. Among
these, three patients were also prescribed two additional an-
tipsychotics. Two patients were prescribed combinations of
two antipsychotics and two anxiolytics-hypnotics, while
one patient were prescribed a combination of two antide-
pressants and three anxiolytics-hypnotics. One patient was
prescribed three concurrent anxiolytics-hypnotics. The in-
crease in PICP was associated with anxiolytic-hypnotics,
while a reduction in prescription of several concurrent anti-
psychotics or antiepileptics was observed. PIPS were re-
duced from 2000 to 2016, but an increase in prescription of
diazepam was observed.
PIs
The median number of PIs was 1 in both 2000 and
2016. Sixty-three patients had 94 PIs in 2000 increasing
to 146 patients with 236 PIs in 2016. A range of one to
four concurrent PIs in 2000 increased to one to nine in
2016. The three psychotropics most frequently pre-
scribed to patients with PIs in 2000 were citalopram (22
patients), risperidone (16 patients) and zopiclone (13 pa-
tients). The three psychotropics most frequently pre-
scribed to patients with PIs in 2016 were oxazepam (90
patients), mirtazapine (77 patients) and zopiclone (51
patients). Table 4 shows classification of first ranked PIs
with the most frequent psychotropics involved. Mecha-
nisms of the interactions with the associated level of
documentation are described. First ranked PIs consti-
tuted 67% of all interactions in 2000 and 62.7% in 2016.
First ranked PIs were increasingly pharmacodynamic
Table 2 Psychotropics prescribed to patients in 2000 and 2016 in three nursing homes with 386 and 416 patients the respective
years
2000 2016 p-value
Patients n (%) n (%) Patients n (%) n (%)
All patients 386 (100.0) 416 (100.0)
Antidepressants 97 (25.1) 170 (40.9) < 0.001
Antipsychotics 91 (23.6) 130 (31.3) 0.015
Anxiolytics-hypnotics 102 (26.4) 268 (64.4) < 0.001
Antiepileptics 29 (7.5) 49 (11.8) 0.042
One or more drugs 230 (59.6) 335 (80.5) < 0.001
Antidepressants 97 (42.2) 170 (50.7) 0.045
Antipsychotics 91 (39.6) 130 (38.8) 0.856
Anxiolytics-hypnotics 102 (44.3) 268 (80.0) < 0.001
Antiepileptics 29 (12.6) 49 (14.6) 0.494
Two or more drugs 94 (24.4) 233 (56.0) < 0.001
Antidepressants 53 (56.4) 151 (64.8) 0.155
Antipsychotics 53 (56.4) 114 (48.9) 0.222
Anxiolytics-hypnotics 65 (69.1) 203 (87.1) < 0.001
Antiepileptics 14 (14.9) 47 (20.2) 0.347
Three or more drugs 24 (6.2) 123 (29.6) < 0.001
Antidepressants 17 (70.8) 97 (78.9) 0.389
Antipsychotics 17 (70.8) 72 (58.5) 0.260
Anxiolytics-hypnotics 20 (83.3) 116 (94.3) 0.062
Antiepileptics 6 (25.0) 35 (28.5) 0.730
≥ 1 interaction 63 (16.3) 146 (35.1) < 0.001
Antidepressants 43 (68.3) 134 (91.8) < 0.001
Antipsychotics 38 (60.3) 63 (43.2) 0.023
Anxiolytics-hypnotics 36 (57.1) 124 (84.9) < 0.001
Antiepileptics 11 (17.5) 29 (19.9) 0.347
Chi-square test was used for comparison of proportions. Notice that patients can be prescribed several concurrent categories of psychotropics. Categories of
psychotropics are associated with patients with interactions, but not necessarily involved in the interactions
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with a decreased level of recommended action and
documentation, but not severity. First ranked PIs in-
volved three PIPS in 2000 and none in 2016. Antipsy-
chotics were frequently involved in first ranked PIs in
2000 while antidepressants were frequently involved in
2016. Pharmacodynamic PIs mainly concerned risk of
sedation based on theoretical documentation. Twelve PIs
that should be avoided concerned risk of QT-prolongation
irrespective of psychotropics involved (not only those
listed in Table 4). Other PIs ranked as severe concerned
risk of the serotonin syndrome. Pharmacokinetic PIs
involved as expected a change in plasma levels of one or
both drugs, and pharmacokinetic PIs were frequently
based on study.
Outcomes and predictors
The variance inflation factors were < 2.0 and tolerance
values were > 0.5 for all predictors in multicollinearity
analysis in both 2000 and 2016. Predictors for having PIs
from the univariate logistic regression analysis with p <
0.25 that could be included in the multivariable logistic
regression analysis was number of psychotropics and
Table 3 Prescription of combinations of psychotropic drugs, PICP and PIPS in 2000, and 2016, among patients in three nursing
homes with 386 and 416 patients the respective years
2000 2016 p-value
Patients n (%) n (%) Patients n (%) n (%)
Combination of categories 80 (20.7) 210 (50.5) < 0.001
Antidepressants + antipsychotics 26 (32.5) 62 (29.5) 0.622
Antidepressants + anxiolytics-hypnotics 32 (40.0) 127 (60.5) 0.002
Antidepressants + antiepileptics 2 (2.5) 28 (13.3) 0.005
Antipsychotics + anxiolytics-hypnotics 31 (38.8) 95 (45.2) 0.319
Antipsychotics + antiepileptics 4 (5.0) 15 (7.1) 0.605
Anxiolytics-hypnotics + antiepileptics 10 (12.5) 38 (18.1) 0.252
Potentially inappropriate combinations of psychotropic drugs (PICP) 30 (7.8) 116 (27.9) < 0.001
Two or more antidepressants 6 (20.0) 40 (34.5) 0.153
Two or more antipsychotics 11 (37.0) 8 (6.9) < 0.001
Two or more anxiolytics-hypnotics 7 (23.0) 86 (74.1) < 0.001
Two or more antiepileptics* 5 (17.0) 1 (0.9) 0.001
Two or more psychotropic drugs with anticholinergic effects 3 (10.0)
Potentially inappropriate psychotropic drugs (PIPS) 69 (17.9) 47 (11.3) 0.008
Long acting benzodiazepines
Diazepam 14 (20.3) 33 (70.2)
Flunitrazepam 5 (7.2) 0
Nitrazepam 11 (15.9) 2 (4.3)
Psychotropic drugs with anticholinergic effects
Antidepressants
Amitriptyline 8 (11.6) 2 (4.3)
Clomipramine 1 (1.4) 0
Nortriptyline 6 (8.7) 0
Antipsychotics
Chlorpromazine 7 (10.1) 0
Chlorprotixene 2 (2.9) 3 (6.4)
Levomepromazine 18 (26.1) 4 (8.5)
Prochlorperazine 2 (2.9) 0
Anxiolytics-hypnotics
Hydroxyzine 3 (4.3) 3 (6.4)
Chi-square or Fischer’s exact test was used for comparison of proportions. Notice that patients can be prescribed several concurrent categories of psychotropics.
The denominator in the calculations was chosen to find the most frequent inappropriate prescribing within Combination of categories, PICP and PIPS. *Not
included in definition of PICP
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prescription of antidepressants, antipsychotics (only in
2016), and anxiolytics-hypnotics. In multivariable ana-
lysis only number of psychotropics was predictive of
having PIs in 2000. In 2016, number of psychotropics
and prescription of antidepressants were predictive of
having PIs (Table 5).
Discussion
The present study found a significant change in inappro-
priate prescribing of psychotropics in three Norwegian
nursing homes audited 16 years apart. Using prescribing
quality indicators we observed that antidepressants and
anxiolytics-hypnotics were more frequently inappropri-
ately prescribed in the present decade. In contrast,
antipsychotics and antiepileptics were less frequently in-
appropriately prescribed compared to the previous dec-
ade. Furthermore, the prescribing quality indicators also
showed that inappropriate prescribing of psychotropics
in 2016 was associated with increased polypharmacy and
PIs, mainly pharmacodynamic, with a low level of docu-
mentation. In the following, the results are discussed
with relevance for medical informatics.
The increase in PIs was associated with prescribing of an-
tidepressants. The proportion of patients with PIs in 2016
was almost doubled compared to 2000, although contrain-
dicated PIs were reduced. Among first ranked PIs, an
increased proportion was pharmacodynamic with mecha-
nisms mainly based on theoretical documentation. Only
nine of all 179 (5 %) pharmacodynamic first ranked PIs in
the present results were based on studies. High quality
documentation to support the existence of many drug in-
teractions is still lacking [20, 21]. Low quality documenta-
tion could result in failure to recognise drug interactions
(sensitivity) or risk of misclassification (specificity). Poor
inter-rater agreement was observed in a small study with
two groups of eight general practitioners who reviewed 100
randomly selected drug interactions according to available
documentation and their clinical experience. In 97 out of
100 interactions there was at least some disagreement on
whether the interaction was clinically significant [22].
The most serious PIs concerned QT-interval prolonga-
tion and the serotonin syndrome. However, both condi-
tions are associated with a low level of documentation and
controversy. QT-interval prolongation is regarded as a po-
tential serious effect of psychotropics with risk of sudden
cardiac death [23]. However, drugs that prolong the
QT-interval range from having potent torsadogenic activ-
ity to no proarrhythmic action and even antiarrhythmic
effects [24]. Two recent studies found no correlation be-
tween the number of QT-prolonging drugs in a patient
and degree of corrected QT (QTc) prolongation [25, 26].
Several authors state that QT-prolongation is a bad surro-
gate for serious ventricular arrhythmias [24, 27, 28]. The
serotonin syndrome is a potentially fatal and largely avoid-
able adverse drug reaction caused by serotonergic drugs
[29]. Associations and cautions concerning the rare but
serious serotonin syndrome have proliferated in the med-
ical literature [29]. Clinicians prescribing serotonin re-
uptake inhibitors (SSRIs) can expect to be warned about
1000 interaction drugs where the majority have little or no
evidence of an interaction.
Risk of sedation by combining two or more psychotro-
pics was the most frequent mechanism among all the
first ranked PIs, but also among all the other PIs in the
material irrespective of year. A study among 455 resi-
dents in a long-term care setting found that the alerts
most often triggered by prescribing were risk of sedation
[30]. However, drug interaction alerts are frequently
overridden. A hospital study found that 93% of alerts
from an electronic medical record and clinical decision
system were overridden with no difference between ex-
perienced or unexperienced physicians [31]. The most
common overall reason for overriding alerts was, ac-
cording to another study, the patient had previously
Table 5 Univariate and multivariate logistic regression analyses of predictive variables for having psychotropic interactions in 2000,
and 2016, among patients in three nursing homes with 386 and 416 patients the respective years
Predictive variables 2000 2016
n = 386 n = 416
Unadjusted model Adjusted model Unadjusted model Adjusted model
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Gender 1.60 (0.59–4.31) 0.358 1.26 (0.72–2.18) 0.425
Age 0.99 (0.94–1.05) 0.741 0.99 (0.96–1.02) 0.457
Number of psychotropic drugs 4.28 (1.25–14.64) 0.021 6.06 (1.61–22.81) 0.008 2.95 (1.97–4.42) < 0.001 2.58 (1.43–4.63) 0.002
Prescribed antidepressants 4.52 (1.80–11.34) 0.001 3.18 (1.12–9.04) 0.030 45.98 (20.80–101.67) < 0.001 29.00 (12.23–68.77) < 0.001
Prescribed antipsychotics 1.62 (0.68–3.86) 0.274 0.54 (0.31–0.92) 0.023 0.61 (0.24–1.51) 0.282
Prescribed anxiolytics-hypnotics 0.09 (0.02–0.42) 0.002 0.07 (0.02–0.35) 0.001 0.57 (0.24–1.35) 0.200 0.51 (0.15–1.78) 0.293
Prescribed antiepileptics 1.97 (0.51–7.67) 0.326 0.95 (0.49–1.84) 0.879
OR Odds ratio, CI Confidence interval
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tolerated the medication [32]. A potential relevant obser-
vation in the present results is that there were no strati-
fication to age, gender or dose when examining the
pharmacodynamic PIs [19].
Pharmacokinetic PIs in drug interaction databases are
frequently supported by studies. In the present results, 15
of the 30 pharmacokinetic PIs (50.0%) were based on stud-
ies. Studies and case reports provide description of clinical
and laboratory monitoring and management options with
dose adjustments that can be included in prescribing tools.
It is plausible the reduction in pharmacokinetic PIs from
2000 to 2016 could reflect more awareness among pre-
scribers due to improved quality of the documentation. To
support this, we observed a reduction in prescription of
drugs with risk of pharmacokinetic interactions like carba-
mazepine, paroxetine, phenobarbital and phenytoin be-
tween 2000 and 2016.
The general increase in use of psychotropics from
2000 to 2016 mainly concerned anxiolytics-hypnotics
and antidepressants with a substantial increase in psy-
chotropic polypharmacy and PICP. Psychotropic poly-
pharmacy was found in 14.5% of residents on a regular
basis in recent study of 881 patients from 30 Norwegian
nursing homes. In that study, a higher risk was found in
female residents, residents residing in long-term wards,
and residents with the best performance in activities of
daily living [15]. In the present study, a high proportion
of polypharmacy (30%) may in part be explained by in-
cluding drugs on demand. Yet, the reduction in PIPS we
observed from 2000 to 2016 is not necessarily explained
by improved medical informatics and increased aware-
ness. Several PIPS are no longer licensed in Norway and
have been replaced by new psychotropics. Prescribing in
2016 of diazepam and clomethiazole to nearly 8 and 5%
of the patients respectively, was surprising since these
drugs are not recommended in this population [15].
However, nearly 50% of diazepam was prescribed as
needed for epileptic seizures, and the other 50% were
equally divided between regularly prescribed and as
needed. The other prescriptions was PIPS with anti-
cholinergic effects have been associated with risk of cog-
nitive decline. However, a single blind randomized trial
in Norway found no improvements in cognitive function
eight weeks after reducing anticholinergic drugs in pa-
tients at nursing homes [33]. Furthermore, it has been ar-
gued that patients with cognitive decline could have
symptoms that result in anticholinergic prescriptions [34].
Increase in PICP in 2016 was related to combinations of
zopiclone and oxazepam, both frequently prescribed
drugs. Anxiolytics and hypnotics used routinely or as
needed can lead to polypharmacy, potentially harmful
drug interactions, and total drug doses exceeding the
maximum recommended [18]. Less rational combinations
like two antidepressants and two anxiolytics-hypnotics
were also observed. Increased use of antidepressants and
anxiolytics-hypnotics has been reported in several recent
studies in Norwegian nursing homes [35–37]. A recent
study found a significant decrease in prescribing of anti-
psychotic drugs to patients with mild dementia between
2004 and 2014 with no change in prescription of other
psychotropics [38]. In the present results the proportion
of patients with antipsychotics did not increase signifi-
cantly, and was reduced among patients with PIs and in
particular among patients with PICP from 2000 and 2016.
A possible explanation is that reduced prescribing of anti-
psychotic drugs for behavioural symptoms is compensated
by increased prescription of other categories of psychotro-
pics [35, 39]. Increased risk of cerebrovascular adverse ef-
fects and mortality in elderly patients has been associated
with conventional and atypical antipsychotics in several
studies [40, 41]. U.S Food and Drug Administration warn-
ings of increased risk of death associated with atypical (in
2005) and conventional (in 2009) antipsychotics in pa-
tients with dementia gained attention in Norwegian drug
information sources. Stabilization or a reduction in pre-
scribing of antipsychotics in nursing homes suggests that
medical informatics could have some success in increasing
awareness for this category of psychotropics in nursing
homes. However, antipsychotic drug use was not associ-
ated with long-term mortality risk among 1163 patients
over a 75-month follow-up period in Norwegian nursing
home patients [42].
The importance of antidepressants and anxiolytics-
hypnotics for inappropriate prescribing in the present
decade could be related to several factors. The use of
these psychotropics for behavioural symptoms to com-
pensate for reduced prescribing of antipsychotics has
been mentioned above. Changes in organisation, staff ex-
pectations, drug safety perception, drug licence policy,
and demographic and clinical characteristics of patients
are among other possible factors. However, from a med-
ical informatics perspective prescribing to nursing home
patients should focus on drug safety irrespective of pa-
tient factors. In our opinion, the more ill patients should
at least avoid inappropriate drugs and drug combina-
tions. Notably, prescribing quality indicators of relevance
in 2000 could be redundant in 2016 due to a change in
clinical practice and available drugs on the market. Fur-
thermore, low specificity (e.g. it is rational to use of diaze-
pam in epileptic seizures) or a low level of documentation
(e.g. pharmacodynamic PIs) could contribute to ignorance
of alerts.
Strength and Limitations
Classification of PIs in both 2000 and 2016 was per-
formed using a single subscription database updated in
2017. However, this database scores statistically high
with regard to ownership, classification of interactions,
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primary information sources and staff qualification in
comparison with open access drug interaction databases
[14]. Prescribing indicators like PICP and PIPS have
been used in several research studies [12, 43]. The nurs-
ing homes included in the present study had access to
modern prescribing tools. From 2007/2008, two of the
nursing homes had access to pilot a computerized deci-
sion support system called the Geriatric Basis Dataset
(GBD), which included the interaction tool in the Nor-
wegian Pharmaceutical Product Compendium, while the
third nursing home gained access to pilot the system in
2012. Furthermore, GBD include The Norwegian Gen-
eral Practice (NORGEP) criteria for prescribing to eld-
erly > 70 years [43].
Limitations include the theoretical approach of this small
study, lack of clinical information, lack of information about
other drugs, and information concerning organisation and
staff within the institutions. The respective patient popula-
tions in 2000 and 2016 could be quite different since the
nursing homes had more specialized units in 2016. In-
creased comorbidity, dementia and polypharmacy among
the patients could warrant more or different psychotropics.
Only one drug interaction database was used for classifica-
tion of clinically relevant PIs while it is well known that
drug interaction databases lacks consistency [20, 21]. Fur-
thermore, the most important PI in each patient (about
63-67% of all PIs) was used to describe qualities of psycho-
tropic interactions, while use of other databases could pro-
vide different ranking. Only potential PIs are described, and
all prescriptions (regular and on demand) were included
which may increase the risk of overestimating daily use of
psychotropics. Anxiolytics and hypnotics as a single cat-
egory could also overestimate PICP.
Conclusions
In this small Norwegian study, we observed an increasing
importance of antidepressants and anxiolytics-hypnotics for
inappropriate prescribing of psychotropics in nursing
homes in 2016 compared to 2000. Prescribing quality indi-
cators found that the inappropriateness of psychotropics in
2016 were associated with mainly pharmacodynamic inter-
actions, lack of good documentation, and controversial as-
sertions. The relevance of these qualities for the persistent
problem of inappropriate prescribing of psychotropics in
nursing homes, and if this reduces the impact of decision
support systems, is of interest to study. Furthermore, our
identification of the main drug categories for inappropriate
prescribing in nursing homes in this decade could be used
for planning specific medical informatics-based approaches
in these institutions. A suggestion would be to address use
of antidepressants and anxiolytic-hypnotics in Norwegian
nursing homes through an academic detailing program.
Furthermore, we suggest a revision of prescribing quality
indicators in cooperation with the prescribers themselves.
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